First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.
Jie Zhang, Xiaojia Wang, Huiting Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I, open-label, multicenter trial evaluated the safety and preliminary efficacy of the PARP inhibitor HWH340 in patients with advanced solid tumors, particularly those with homologous recombination repair gene mutations. The study established 200 mg BID as the recommended Phase 2 dose, with an objective response rate of 19.5% in the overall cohort and 41.7% in patients with BRCA1/2 mutations.
Key findings
- The objective response rate (ORR) was 19.5% among 41 evaluable patients.
- Patients with BRCA1/2 mutations in the 200 mg group had an ORR of 41.7%.
- The disease control rate (DCR) was 56.1% in the overall cohort.
- No dose-limiting toxicities were detected, indicating good tolerability.
Why it matters
The study highlights the potential of HWH340 as a treatment option for patients with advanced solid tumors harboring HRR mutations, particularly BRCA1/2 mutations, which may influence future therapeutic strategies in oncology.
What to keep in mind
The small sample size and patient heterogeneity limit the generalizability of the findings.